|
| Status |
Public on Sep 05, 2017 |
| Title |
LNCAP treated with 10 nM DHT for 16h, biological rep2 |
| Sample type |
RNA |
| |
|
| Source name |
Androgen-sensitive human prostate adenocarcinoma cells
|
| Organism |
Homo sapiens |
| Characteristics |
treatment: 10 nM DHT (16h)
|
| Treatment protocol |
LNCaP cell were seeded to 8x105 cell per 10cm dish and starved for 3 days in RPMI Medium 1640-no-phenol red (Gibco) and 5% chracoal stripped FVBS (CSFBS). Then LNCaP cells were treated with or without (vehicle, ETOH) 10nM of DHT for 30mins, 2h, 4h and 16h. Cells were then harvested for RNA extraction
|
| Growth protocol |
Human LNCaP prostate cancer cells were maintained in RPMI Medium 1640 (Gibco) supplemented with 10% fetal bovine serum (FBS), for at least 72 hrs to 70-80% confluence before seeding for starvation and DHT treatment.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA extraction was performed using Trizol Reagent (invitrogen) following manufacturer's instructions
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol for the Human 2.1ST arrays
|
| |
|
| Hybridization protocol |
As per standard Affymetrix protocol for the Human21.1ST arrays
|
| Scan protocol |
As per standard Affymetrix protocol for the Human21.1ST arrays
|
| Description |
DHT time-series gene expression
|
| Data processing |
Data were processed in R using the rma function in the Oligo package
|
| |
|
| Submission date |
Dec 24, 2015 |
| Last update date |
Sep 05, 2017 |
| Contact name |
Fatima Valdes Mora |
| E-mail(s) |
f.valdesmora@garvan.org.au
|
| Phone |
+61 2 92958334
|
| Organization name |
Garvan Institute of Medical Research
|
| Department |
Genomics and Epigenetics
|
| Lab |
Histone Variant Group
|
| Street address |
384 Victoria Street
|
| City |
Darlinghurst |
| State/province |
NSW |
| ZIP/Postal code |
2010 |
| Country |
Australia |
| |
|
| Platform ID |
GPL17692 |
| Series (2) |
| GSE76335 |
Novel contribution of acetylated histone variant H2A.Z in activation of neo-enhancers in prostate cancer [Microarray expression] |
| GSE76337 |
Novel contribution of acetylated histone variant H2A.Z in activation of neo-enhancers in prostate cancer |
|
